1. Introduction {#sec0005}
===============

The ongoing pandemic of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causing the coronavirus disease 2019 (COVID-19) has imposed an increasing demand on daily diagnostic screening. This is expected to perpetuate over the coming months, due to the recurrence of outbreaks and lifting of lockdown measures worldwide ([@bib0035]). Given the high sensitivity compared to serological testing ([@bib0010]), standard diagnosis continues to rely on RNA extractions from respiratory or oral samples followed by one-step reverse transcription and real-time quantitative polymerase chain reaction (RT-qPCR) that entails one or several primer-probe sets for targeting SARS-CoV-2 sequences ([@bib0015]). While it has been shown that protocol modifications aiming to overcome supply chain issues and accelerate diagnosis affect assay sensitivity ([@bib0005], [@bib0020]), differences in target priming efficiencies and RT-qPCR kit components are also expected to account for dissimilarities in false negative results ([@bib0025]).

This study aimed to evaluate the sensitivity of six different RT-qPCR solutions, including five marketed kits and one based on the World Health Organization (WHO) diagnostic assays with the best sensitivity ([@bib0015], [@bib0045]), using RNA extractions from nasopharyngeal swab viral transmission medium (VTM). To skip the RNA extraction step that has been described elsewhere, the alternative with the best sensitivity was also assessed by direct preheating of VTM samples ([@bib0005]).

2. Materials and methods {#sec0010}
========================

The study was conducted at the University Hospital Nuestra Señora de Candelaria (Santa Cruz de Tenerife, Spain) from March to June 2020. Six different RT-qPCR solutions were evaluated ([Table 1](#tbl0005){ref-type="table"} ): four based on three viral targets and two based on one viral target. Given the high specificity of the RT-qPCR ([@bib0005]), focus was on evaluating the rate of false negatives (FN) and assay sensitivity using the same 98 COVID-19 patient samples. The alternative with the best sensitivity was also assessed under an alternative procedure that skips the RNA extraction step described elsewhere ([@bib0005]).Table 1Different RT-qPCR solutions evaluated for the detection of SARS-CoV-2 in nasopharyngeal swab samples from COVID-19 positive patients.Table 1Solution\#Targets[a](#tblfn0005){ref-type="table-fn"}Target geneSensitivity, % (95% CI)[b](#tblfn0010){ref-type="table-fn"}FN[c](#tblfn0015){ref-type="table-fn"}TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher Scientific) combined with validated primer-probe sets[d](#tblfn0020){ref-type="table-fn"}3E95.9 (89.9--98.9)4N75.5 (65.8--83.6)24RdRp77.6 (68.0--85.4)22LightMix® Modular SARS-CoV (COVID19) (TIB MOLBIOL)3E97.9 (92.8--99.7)2N78.6 (69.1--86.2)21RdRp89.8 (82.0--95.0)10SARS-COV-2 R-GENE (BioMérieux)3E65.3 (55.0--74.6)34N66.3 (56.1--75.6)33RdRp60.2 (49.8--70.0)39TaqPath COVID-19 CE-IVD RT-PCR Kit (Thermo Fisher Scientific)3ORF1ab65.3 (55.0--74.6)34S70.4 (60.3--79.2)29N76.5 (66.9--84.5)23Genesig Real-Time PCR COVID-19 kit (Primedesign Ltd.)1RdRp81.6 (72.5--88.7)18Real Accurate Quadruplex corona-plus PCR Kit (PathoFinder)1N83.7 (74.8--90.4)16[^1][^2][^3][^4]

Samples were collected in 2 mL of VTM (BioMérieux, Lyon, France). RNA extractions were conducted from 200 μL of VTM using the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche, Basel, Switzerland) or the STARMag Viral DNA/RNA 200C kit (Seegene, Seoul, Korea). The RT-qPCR was performed in 10 μL final volume reactions (5 μL of sample) using a CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, California, USA) following the thermal cycling specifications of each solution. Positive and negative controls were included in all experiments, as described elsewhere ([@bib0005]). Sensitivity and 95% confidence intervals (95% CI) were calculated from the FN counts using MedCalc (MedCalc Software Ltd.).

3. Results {#sec0015}
==========

Since all samples were COVID-19 positive for at least one solution/viral target, results with threshold cycle (Ct) values \>40 or those that remained undetected during the 45 cycles of the experiments were considered FN observations ([Fig. 1](#fig0005){ref-type="fig"} , [Table 1](#tbl0005){ref-type="table"}). Attending to individual targets, it was found that the most sensitive solution was the LightMix® Modular SARS-CoV (COVID19) (TIB MOLBIOL, Berlin, Germany) used in combination with a primer-probe set for the E-gene (97.9% \[92.8--99.7\]) ([Table 1](#tbl0005){ref-type="table"}). It was closely followed by the TaqMan Fast Virus 1-Step Master Mix kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA) combined with validated primer-probes for diagnosis ([@bib0015]) for the same viral gene (95.9% \[89.9--98.9\]). When combining at least two viral gene targets, it was found that the TaqMan Fast Virus 1-Step Master Mix kit with validated primer-probe sets targeting both E and RdRp genes ([@bib0015]) attained an equivalent sensitivity. The kit with the poorest performance for all three viral primer-probe sets was SARS-COV-2 R-GENE (BioMérieux) (range 60.2% \[49.8--70.0\] to 66.3% \[56.1--75.6\]). Its levels of sensitivity improved to those of all other kits when the E-gene primer-probe set was combined with those for N or the RdRp genes (71.4% \[61.4--80.1\] and 69.4% \[59.3--78.3\], respectively). The sensitivity of all other solutions did not benefit from combining the results of more than one primer-probe set.Fig. 1Raincloud plot of the distribution of cycle threshold (Ct) values for the RT-qPCR solutions evaluated for the detection of SARS-CoV-2 in COVID-19 positive samples. Raw Ct data with the median and the interquartile range are also represented and overlaid on each distribution.Fig. 1

Finally, because the LightMix® Modular SARS-CoV (COVID19) kit with primer-probes for the E-gene showed the highest sensitivity, it was tested on samples that were preheated at 70 °C for 10 minutes in a substitution of the RNA extraction ([@bib0005]). Although this alternative decreased the kit sensitivity (72.5% \[62.5--81.0\]), the results were still comparable with other evaluated solutions ([Table 1](#tbl0005){ref-type="table"}).

4. Discussion {#sec0020}
=============

RT-qPCR for selected target genes of SARS-CoV-2 has been key in the global response to the COVID-19 pandemic. Given the rapid spread of the virus at this time, it is likely that the RT-qPCR assays will continue to be a central tool for controlling COVID-19. However, as happened in the past due to supply chain issues, policy decisions and laboratory testing capacities ([@bib0005]), it is predictable that the diagnosis of COVID-19 will continue relying on a variety of solutions among laboratories and countries ([@bib0045]).

The current results showed a wide variability in the sensitivity of RT-qPCR solutions for SARS-CoV-2 detection, which was associated with a proportion of FN ranging from 2% (0.3--7.9%) to 39.8% (30.2--50.2). Given that the same patient nasopharyngeal samples were assayed for different solutions, well-known factors affecting SARS-CoV-2 sensitivity (stage of infection and type of specimen) ([@bib0030], [@bib0050]) were suitably controlled in the study, since all solutions were equally affected. Thus, the differences in sensitivity among solutions were due to their different components (i.e. primers-sets, buffers, enzymes, and reagent contents in general). These findings will help to assess the impact of the selected solution on FN diagnoses of COVID-19 ([@bib0040]) and to choose a solution that minimizes misdiagnoses of an active SARS-CoV-2 infection.
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